Therefore, we showed that ICAM-1 served as a crucial effector in the dual-directional ways of CX3CL1 to generate interactions with circulating NSCLC cells in NSCLC spinal metastasis and implied that pharmacological inhibition of ICAM-1 signaling may reduce the development of spinal metastasis in clinic. This evidence concerns the gene CX3CL1 and non-small cell lung carcinoma.